Blood pressure (BP)-lowering treatment significantly reduces the risk of major cardiovascular events in individuals with chronic kidney disease (CKD) across all stages, with effects comparable to those without CKD, although benefits are diminished in patients with coexisting diabetes. This one-stage individual-participant meta-analysis included 52 randomized controlled trials, of which 46 […]
While myocardial infarction (MI) accounts for a substantial proportion of sudden cardiac deaths (SCDs), most arrhythmic SCDs occur in individuals without previously diagnosed risk factors, often due to occult cardiac disease such as silent MI or dilated cardiomyopathy. In the 12-year US countywide POST SCD autopsy study, 943 presumed sudden […]
In patients with established cardiovascular disease (CVD), calcium supplementation was associated with an increased risk of recurrent CVD events and related hospitalizations, particularly with calcium-only use and among men. In this large retrospective population-based study from Hong Kong, 17,720 matched patients receiving calcium supplements were compared with an equal number […]
In high-risk patients with diabetes but no known significant atherosclerosis, treatment with evolocumab significantly reduced the risk of a first major cardiovascular event compared with placebo when added to statin therapy. This prespecified subgroup analysis of the VESALIUS-CV randomized, double-blind, placebo-controlled trial included 3,655 participants from 774 sites across 33 […]
Achieving remission of prediabetes was associated with an approximately 50% lower long-term risk of death from cardiovascular disease (CVD) or hospitalization for heart failure, with benefits persisting for decades in two landmark diabetes prevention cohorts. In post hoc analyses of the US Diabetes Prevention Program Outcomes Study and the Chinese […]
In nearly 450,000 adults without known atherosclerotic cardiovascular disease (CVD), elevated high-sensitivity C-reactive protein (hsCRP) independently predicted major adverse CVD events and mortality, outperformed several conventional risk factors, and significantly improved the Systematic COronary Risk Evaluation 2 (SCORE2)-based risk prediction. In this UK Biobank study, participants had a median age […]
In a population-based analysis of 371,032 UK Biobank participants, faster biological aging in males explained a substantial proportion of their higher cardiovascular disease (CVD) risk compared with females, accounting for about 60–68% of the excess risk across major CVD outcomes. Although males and females had similar chronological ages, males consistently […]
A systematic review of 17 randomized trials involving 66,337 adults found that reducing or modifying saturated fat intake offers little or no clinically meaningful benefit over five years for people at low cardiovascular risk, but may lead to important reductions in mortality and major cardiovascular events among those at high […]
Low-dose colchicine reduces myocardial infarction and stroke in people with cardiovascular disease (CVD) without increasing serious adverse events, although it raises the risk of mild gastrointestinal symptoms and shows no clear effect on mortality or revascularization. In an updated Cochrane review of 12 randomized controlled trials including 22,983 participants followed […]
Daily supplementation with n−3 polyunsaturated fatty acids (fish oil) significantly reduced the risk of serious cardiovascular events in patients receiving maintenance hemodialysis. In a double-blind, randomized, placebo-controlled trial across 26 sites in Canada and Australia, 1,228 adults on hemodialysis were assigned to receive either 4 g of fish oil daily […]